Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 50

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
 31,2025March 31,2024(unaudited)(unaudited)Total revenues$149,824 $143,644 Less: Significant segment expenses:Cost of goods sold15,763 16,309 Selling42,614 39,014 Marketing20,664 20,553 General and administrative26,666 26,949 Research and development expensesExternal development program expenses:ONAPGO472 784 SPN-8204,763 6,738 SPN-8173,571 1,122 Qelbree4,413 2,051 Early-stage programs and other expenses3,213 4,015 Total external development program expenses16,432 14,710 Internal employee-related expenses10,495 10,220 Total research and development expenses26,927 24,930 Other segment items(a)29,017 15,765 Net earnings (loss)$(11,827)$124 (a) Other segment items include amortization of intangible assets, intangible asset impairment charges, contingent consideration gain or loss, net interest and other income, interest expense, and income tax expense, whose amounts are disclosed in the condensed consolidated statement of earnings (loss).

14.    Composition of Other Balance Sheet Items

The following details the composition of other balance sheet items (dollars in thousands for amounts in tables):

Inventories, Net March 31,2025December 31,2024(unaudited)Raw materials$8,664 $11,127 Work in process18,694 26,725 Finished goods22,065 16,441 Total$49,423 $54,293 

18

Property and Equipment, Net March 31,2025December 31,2024(unaudited)Lab equipment and furniture$13,760 $13,370 Leasehold improvements14,023 14,023 Software883 883 Computer equipment1,112 1,112 29,778 29,388 Less accumulated depreciation and amortization(18,440)(17,843)Property and equipment, net$11,338 $11,545 Depreciation and amortization expense on property and equipment was approximately $0.6 million for the three months ended March 31, 2025 and $0.6 million for the three months ended March 31, 2024, respectively.

Accounts